TABLE 1.
Demographics of study cohorts at start of antifibrotic therapy.
| Characteristics | Healthy volunteers (n = 16) | IPF cohort 1 (n = 122) | IPF Cohort 2 (n = 21) | p-value (Cohort 1 vs. Cohort 2) |
|---|---|---|---|---|
| Antifibrotic treatment, n (% of IPF) | - | 122 (100) | 21 (100) | |
| Nintedanib | - | 67 (55) | 15 (71) | |
| Pirfenidone | - | 55 (45) | 6 (29) | |
| Age (years), median (IQR) | 65 (61–73)a | 72 (65–76) | 65 (62–73) | 0.042 |
| Female gender, n (%) | 6 (38) | 27 (22) | 2 (10) | 0.193 |
| Forced vital capacity at baseline (% predicted), median (IQR) | 118 (105–132) | 68 (57–80) | 83 (72–94) | <0.001 |
| GAP Index | - | 0.001 | ||
| I | 34 (28) | 12 (67) | ||
| II | 65 (53) | 6 (33) | ||
| III | 23 (19) | - | ||
| Comorbidities, n (%) | - | |||
| Coronary artery disease | 38 (31) | 9 (42) | 0.400 | |
| Diabetes mellitus | 26 (21) | 7 (33) | 0.302 | |
| Arterial Hypertension | 47 (38.5) | 13 (62) | 0.080 | |
| Chronic kidney disease | 5 (4) | 0 | 0.328 | |
| Chronic pulmonary obstructive disease | 2 (10) | 12 (10) | 0.890 | |
| Previous smoking history | 73 (60) | 15 (71) | 0.513 |
GAP, Gender; Age, and Physiology index; IQR, interquartile range; IPF, idiopathic pulmonary fibrosis.
a
Kruskal Wallis test between healthy volunteers and IPF, cohorts p = 0.023.